Your browser doesn't support javascript.
loading
Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial.
Tian, Jun; Chen, Jonathan H; Chao, Sherry X; Pelka, Karin; Giannakis, Marios; Hess, Julian; Burke, Kelly; Jorgji, Vjola; Sindurakar, Princy; Braverman, Jonathan; Mehta, Arnav; Oka, Tomonori; Huang, Mei; Lieb, David; Spurrell, Maxwell; Allen, Jill N; Abrams, Thomas A; Clark, Jeffrey W; Enzinger, Andrea C; Enzinger, Peter C; Klempner, Samuel J; McCleary, Nadine J; Meyerhardt, Jeffrey A; Ryan, David P; Yurgelun, Matthew B; Kanter, Katie; Van Seventer, Emily E; Baiev, Islam; Chi, Gary; Jarnagin, Joy; Bradford, William B; Wong, Edmond; Michel, Alexa G; Fetter, Isobel J; Siravegna, Giulia; Gemma, Angelo J; Sharpe, Arlene; Demehri, Shadmehr; Leary, Rebecca; Campbell, Catarina D; Yilmaz, Omer; Getz, Gad A; Parikh, Aparna R; Hacohen, Nir; Corcoran, Ryan B.
Afiliação
  • Tian J; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Chen JH; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Chao SX; The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
  • Pelka K; The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
  • Giannakis M; The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
  • Hess J; Gladstone-UCSF Institute of Genomic Immunology, Gladstone Institutes Department of Microbiology and Immunology, UCSF, San Francisco, CA, USA.
  • Burke K; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Jorgji V; The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
  • Sindurakar P; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Braverman J; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Mehta A; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Oka T; The Koch Institute, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Huang M; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Lieb D; The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
  • Spurrell M; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Allen JN; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Abrams TA; The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
  • Clark JW; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Enzinger AC; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Enzinger PC; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Klempner SJ; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • McCleary NJ; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Meyerhardt JA; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Ryan DP; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Yurgelun MB; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Kanter K; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Van Seventer EE; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Baiev I; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Chi G; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Jarnagin J; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Bradford WB; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Wong E; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Michel AG; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Fetter IJ; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Siravegna G; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Gemma AJ; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Sharpe A; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Demehri S; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Leary R; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Campbell CD; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
  • Yilmaz O; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Getz GA; Novartis Institute for Biomedical Research, Cambridge, MA, USA.
  • Parikh AR; Novartis Institute for Biomedical Research, Cambridge, MA, USA.
  • Hacohen N; The Koch Institute, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Corcoran RB; The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Nat Med ; 29(2): 458-466, 2023 02.
Article em En | MEDLINE | ID: mdl-36702949
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Melanoma Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Nat Med Assunto da revista: BIOLOGIA MOLECULAR / MEDICINA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Melanoma Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Nat Med Assunto da revista: BIOLOGIA MOLECULAR / MEDICINA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos